View source for 18274979. IMMUNE RECEPTORS WITH SYNTHETIC CO-STIMULATORY DOMAINS simplified abstract (The Regents of the University of California)

=IMMUNE RECEPTORS WITH SYNTHETIC CO-STIMULATORY DOMAINS=


==Organization Name==

[[:Category:The Regents of the University of California|The Regents of the University of California]]


[[Category:The Regents of the University of California]]

==Inventor(s)==

[[:Category:Wendell A. Lim of San Francisco CA (US)|Wendell A. Lim of San Francisco CA (US)]][[Category:Wendell A. Lim of San Francisco CA (US)]]

[[:Category:Kyle Daniels of San Francisco CA (US)|Kyle Daniels of San Francisco CA (US)]][[Category:Kyle Daniels of San Francisco CA (US)]]

==IMMUNE RECEPTORS WITH SYNTHETIC CO-STIMULATORY DOMAINS - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18274979 titled 'IMMUNE RECEPTORS WITH SYNTHETIC CO-STIMULATORY DOMAINS

==Simplified Explanation==

The patent application describes an engineered immune receptor that contains short linear motifs to bind to other intracellular signaling proteins, nucleic acids encoding the same, cells containing the receptor, and methods of use.

* The engineered immune receptor may be a chimeric antigen receptor (CAR) or chimeric costimulatory receptor (CCR).
* The receptor contains motifs such as PLCδ1-binding motifs and TRAF binding motifs to recruit other proteins and alter cellular responses.

== Potential Applications ==
The technology could be used in cancer immunotherapy, autoimmune disease treatment, and infectious disease therapy.

== Problems Solved ==
This innovation helps enhance the specificity and efficacy of immune cell therapies by modifying cellular responses through the recruitment of additional signaling proteins.

== Benefits ==
The engineered immune receptor can potentially improve the targeting of diseased cells, reduce off-target effects, and enhance the overall effectiveness of immunotherapy treatments.

== Potential Commercial Applications ==
"Enhanced Immune Receptor Technology for Advanced Therapies"

== Possible Prior Art ==
Prior art may include patents or publications related to engineered immune receptors with modified signaling motifs for improved cellular responses.

== Unanswered Questions ==

=== How does the presence of multiple motifs in the engineered immune receptor affect its overall signaling capabilities? ===
The patent application does not provide detailed information on the interplay between different motifs and their combined impact on cellular signaling pathways.

=== What are the potential challenges or limitations in implementing this technology in clinical settings? ===
The article does not address the practical considerations or hurdles that may arise when translating this technology from the lab to real-world applications, such as manufacturing scalability or regulatory approval processes.


==Original Abstract Submitted==

An engineered immune receptor (e.g., a chimeric antigen receptor (CAR) or chimeric costimulatory receptor (CCR)) that contains one or more short linear motifs that bind to other intracellular signaling proteins are provided, as well as nucleic acids encoding the same, cells that contain the same and methods of use. Examples of such motifs include a PLCγ1-binding motifs and TRAF binding motifs, but other motifs may be used. These motifs are thought to recruit other proteins to the engineered immune receptor, thereby altering cellular responses.



[[Category:A61K35/17]]
[[Category:A61K39/00]]
[[Category:A61P35/00]]
[[Category:C07K14/725]]
[[Category:C07K16/28]]